Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

---------------------------------------------------------------

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ materially from any future results expressed or implied by such statements include, but are not limited to: early stage of development; technology and product development; dependence on and management of current and future corporate collaborations; future capital needs; uncertainty of additional funding; no assurance of market acceptance; dependence on proprietary technology and uncertainty of patent protection; intense competition; manufacturing and market uncertainties; and government regulation. These and other factors are described in detail in ARIUS' Annual Report, forthcoming news releases and other filings with Canadian securities regulatory authorities available at http://www.sedar.com. Forward-looking statements are based on our current expectations and ARIUS is not obligated to update such information to reflect later events or developments.


'/>"/>
SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a commercial focus on China , ... (CFDA) has approved the Company,s application to conduct a ... carcinoma (OCCC) patients for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... , March 30, 2015 ... biological drugs to treat cancer, viral infections and ... Sir John Bell , the Regius Professor ... the Office for the Strategic Coordination of Health ... effect.      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ...
(Date:3/29/2015)... , March 29, 2015  Caris ... study data in small cell cervical cancer ... Caris Molecular Intelligence®, the company,s panomic, comprehensive ... gene mutations which may explain sensitivities and ... that identification of certain biomarkers may guide ...
(Date:3/27/2015)... 2015  Peter Walter wurde als Gewinner ... seine bahnbrechende Arbeit ausgewählt, die sich damit ... sowie für die Entschlüsselung der Komponenten eines ... nutzen, der mit der Ansammlung von deformierten ... Biochemie an der University of California, San ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... 9 Millennium: The Takeda,Oncology Company today announced ... in the world, according to Science magazine,s,annual survey ... related industries. With a 2008 ranking of eighth, ... first time, moving up from a 2007 ranking,of ...
... Join Forces to Deliver Patient Care via Single ... Platform, MirixaPro(SM), ... American Pharmacists Association (APhA) Foundation, the creator of,the Diabetes Ten City ... they will form a new partnership that will,deliver all of APhA ...
... Va., Oct. 9 CEL-SCI Corporation,(NYSE: CVM ... of the new,manufacturing facility for its lead drug ... will produce the Multikine that,will be used for ... of previously untreated head and neck cancer patients, ...
Cached Biology Technology:Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine 2Mirixa Corporation and the APhA Foundation Form Partnership 2Mirixa Corporation and the APhA Foundation Form Partnership 3CEL-SCI Takes Delivery of New Manufacturing Facility 2
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
(Date:3/12/2015)... March 12, 2015 Beta ... identity and access management (IAM) solution for a ... With Beta System,s new IAM package, customers benefit ... gleaned from multiple IAM implementations across different industries. ... as well as any necessary services and consulting. ...
(Date:3/10/2015)... , March 10, 2015 ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured ... the past two years. Specifically, "Personalized Medicine ... downloaded scientific papers published in 2013 and 2014 from ...
Breaking Biology News(10 mins):New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... have good reason for engaging in sexual, rather than ... biology in the UI College of Liberal Arts and ... for Genomics. In an article published in a ... Evolution , she and her colleagues, including John M. ...
... YORK, NY (January 21) - New York Stem Cell Foundation ... is lead author on a study defining conditions for generating ... suitable for therapeutic use. Dr. James and his colleagues ... can be used to measure endothelial cell production and activity. ...
... a surprising finding, researchers at North Carolina State University ... believed to be a redundant "on switch" for certain ... Scientists previously understood that the protein called TAB2 ... and prevents invasion of harmful organisms. But scientists considered ...
Cached Biology News:NYSCF Fellow lead author on study that creates blood vessel cells from stem cells 2Inflammation 'on switch' also serves as 'off switch' 2
... MULTI-FUN Incubator is a compact benchtop ... a microprocessor controller with a large ... and agitation speed. Air circulation inside ... incubator. Temperature can be easily calibrated ...
... The CERTOMAT RM is specifically designed as ... densities. The new variable mass compensation allows ... conditions yielding better aeration and, therefore, faster ... orbital shaker is ideal when high reproducibility ...
... The iCycler thermal cycler with 96 ... for nucleic acid amplification (PCR) applications. It ... module (15-100 microliter samples) that is compatible ... features temperature monitoring and control by algorithm, ...
...
Biology Products: